Lincoff A Michael, Steinhubl Steven R, Manoukian Steven V, Chew Derek, Pollack Charles V, Feit Frederick, Ware James H, Bertrand Michel E, Ohman E Magnus, Desmet Walter, Cox David A, Mehran Roxana, Stone Gregg W
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
JACC Cardiovasc Interv. 2008 Dec;1(6):639-48. doi: 10.1016/j.jcin.2008.10.004.
This study sought to determine if the efficacy of bivalirudin alone versus heparin plus a glycoprotein (GP) IIb/IIIa inhibitor is dependent upon the duration of clopidogrel pre-treatment in patients undergoing percutaneous coronary intervention (PCI) in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
The administration of a clopidogrel loading dose several hours before PCI reduces the risk of periprocedural thrombotic events.
Patients with an acute coronary syndrome were randomized to heparin plus a GP IIb/IIIa inhibitor (control), bivalirudin plus a GP IIb/IIIa inhibitor, or bivalirudin alone. Dose and timing of clopidogrel were left to the investigator's discretion.
Of 13,819 patients randomized, 7,789 underwent PCI. When clopidogrel was initiated at any time before angiography or within 30 min after PCI, randomization to bivalirudin alone (n = 2,284) or control (n = 2,189) was associated with similar ischemic outcomes (8.2% vs. 8.3%, risk ratio: 0.98, 95% confidence interval: 0.81 to 1.20). Those patients who received clopidogrel >30 min after PCI or not at all experienced an increase in ischemic events when randomized to bivalirudin alone (n = 290) versus control (n = 317) (14.1% vs. 8.5%, risk ratio: 1.66, 95% confidence interval: 1.05 to 2.63). Major bleeding was significantly less frequent in patients treated with bivalirudin alone.
This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding. If it is anticipated that clopidogrel will be given late or not at all after PCI, bivalirudin alone may be associated with worse ischemic outcomes. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes; NCT00093158).
本研究旨在确定在急性导管插入和紧急干预分诊策略(ACUITY)试验中,接受经皮冠状动脉介入治疗(PCI)的患者单独使用比伐卢定与肝素加糖蛋白(GP)IIb/IIIa抑制剂的疗效是否取决于氯吡格雷预处理的持续时间。
在PCI前数小时给予氯吡格雷负荷剂量可降低围手术期血栓形成事件的风险。
急性冠状动脉综合征患者被随机分为肝素加GP IIb/IIIa抑制剂(对照组)、比伐卢定加GP IIb/IIIa抑制剂或单独使用比伐卢定。氯吡格雷的剂量和给药时间由研究者自行决定。
在13819例随机分组的患者中,7789例接受了PCI。当在血管造影前任何时间或PCI后30分钟内开始使用氯吡格雷时,单独随机接受比伐卢定(n = 2284)或对照组(n = 2189)的缺血性结局相似(8.2%对8.3%,风险比:0.98,95%置信区间:0.81至1.20)。那些在PCI后30分钟以上接受氯吡格雷或根本未接受氯吡格雷的患者,随机接受单独比伐卢定(n = 290)与对照组(n = 317)时,缺血事件增加(14.1%对8.5%,风险比:1.66,95%置信区间:1.05至2.63)。单独使用比伐卢定治疗的患者大出血明显较少见。
这项事后分析表明,在急性冠状动脉综合征患者中,只要在PCI前或PCI后30分钟内给予氯吡格雷,单独使用比伐卢定在抑制30天缺血事件方面与肝素加GP IIb/IIIa抑制剂同样有效,且出血明显较少。如果预计PCI后氯吡格雷给药较晚或根本不给药,单独使用比伐卢定可能与较差的缺血结局相关。(急性冠状动脉综合征中Angiomax与肝素的比较;NCT00093158)